Drugs / Ad5.SSTR/TK.RGD
last change Apr 2012 re-read 2 minutes ago

Ad5.SSTR/TK.RGD

Developed for
ovarian cancer
Investigated by
National Cancer Institute (NCI) · University of Alabama at Birmingham

Trials 1 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00964756 Aug 2009 → Dec 2010 ovarian cancer University of Alabama at Birmingham Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Ad5.SSTR/TK.RGD ClinicalTrials.gov intervention name — accepted as the source's own label NCT00964756
Route Other “Eligible patients were treated intraperitoneally for 3 days with 1 × 10(9) to 1 × 10(12) vp/dose of Ad5.SSTR/TK.RGD” PMID 22510347 Apr 2012